Clinical trial / 2012
Yeast glucopolysaccharide supplementation showed mixed effects on upper respiratory infection symptoms.
A randomized, double-blind, placebo-controlled trial evaluated 250 mg daily yeast-derived 1,3/1,6 glucopolysaccharide or placebo for 90 days in 100 healthy young adults, with 97 completing. The supplement tended to reduce total days with symptoms (198 days, 4.6%, versus 241 days, 5.5%; P = 0.06) and significantly improved the ability to breathe easily, though other severity scores did not differ. Monocyte chemotactic protein-1 was lower during infections with supplementation.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 100 healthy young adults (97 completed)
- What was measured
- Upper respiratory tract infection symptoms and plasma cytokines
THE PAPER
Influence of yeast-derived 1,3/1,6 glucopolysaccharide on circulating cytokines and chemokines with respect to upper respiratory tract infections.
Fuller R, Butt H, Noakes PS, Kenyon J, Yam TS, Calder PC. Nutrition, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.